# Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

> **NCT03474965** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 117 (actual)

## Conditions studied

- Sickle Cell Disease (SCD)

## Interventions

- **DRUG:** Crizanlizumab

## Key facts

- **NCT ID:** NCT03474965
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2024-11-06
- **Final completion:** 2024-11-06
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474965, "Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03474965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*